Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site;Recommandations pour la pratique clinique: Standards, Options et Recommandations 2002 pour le diagnostic des carcinomes de site primitif inconnu

Bulletin du Cancer

Volumn 90, Issue 12, 2003, Pages 1071-1096

  Lesimple, Thierry ^a,c   Voigt, Jean Jacques ^b,c   Bataillard, Anne ^c   Coindre, Jean Michel ^c,d   Culine, Stéphane ^c,e   Lortholary, Alain ^c,f   Merrouche, Yacine ^c,g   Ganem, Gérard ^c,h   Kaminsky, Marie Christine ^c,i   Negrier, Sylvie ^c,j   Perol, Maurice ^c,k   Bedossa, Pierre ^c,l   Bertrand, Gérard ^c,f   Bugat, Roland ^b,c   Fizazi, Karim ^c,m  

^a CENTRE EUGÈNE MARQUIS   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c FNCLCC   (France)

^d INSTITUT BERGONIÉ   (France)

^e CENTRE VAL D AURELLE   (France)

^f CENTRE PAUL PAPIN   (France)

^g Institut de Cancerologie de la Loire   (France)

^h CENTRE JEAN BERNARD   (France)

ⁱ CENTRE ALEXIS VAUTRIN   (France)

^j CENTRE LÉON BÉRARD   (France)

^k CROIX ROUSSE HOSPITAL   (France)

^l BICÊTRE HOSPITAL   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Adult; Carcinoma of unknown primary site; Clinical practice guidelines; CUP; Diagnosis

Indexed keywords

BREAST TUMOR; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GENETICS; CARCINOMA; DIAGNOSTIC APPROACH ROUTE; GERM CELL TUMOR; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MELANOMA; NEUROENDOCRINE TUMOR; OVARY TUMOR; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE TUMOR; REVIEW; SARCOMA; THYROID TUMOR; TUMOR; TUMOR DIFFERENTIATION;

HUMANS; NEOPLASMS, UNKNOWN PRIMARY;

EID: 9144273157     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Fervers B, Bonichon F, Demard F, Héron JF, Mathoulin S, Philip T, et al. Méthodologie de développement des Standards, Options et Recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995 ; 82 : 761-7.
2. Fervers B, Hardy J, Blanc-Vincent MP, Theobald S, Bataillard A, Farsi F, et al. SOR : project methodology. Br J Cancer 2001 ; 84 (Suppl 2) : 8-16.
3. Smith PE, Krementz ET, Chapman W. Metastatic cancer without a detectable primary site. Am J Surg 1967 ; 113 : 633-7.
4. Richardson RG, Parket RG. Metastases from undetected primary cancers. Clinical experience at a radiation oncology center. West J Med 1975 ; 123 : 337-9.
5. Grosbach AB. Carcinoma of unknown primary site : a clinical enigma. Arch Intern Med 1982 ; 142 : 357-9.
6. Gaber AO, Rice P, Eaton C, Pietrafitta JJ, Spatz E, Deckers PJ. Metastatic malignant disease of unknown origin. Am J Surg 1983 ; 145 : 493-7.
7. Kirsten F, Chi CH, Leary JA, Ng AB, Hedley DW, Tattersall MH. Metastatic adeno or undifferentiated carcinoma from an unknown primary site-natural history and guidelines for identification of treatable subsets. Q J Med 1987 ; 62 : 143-61.
8. Haskell CM, Cochran AJ, Barsky SH, Steckel RJ. Metastasis of unknown origin. Curr Pobl Cancer 1988 ; 12 : 5-58.
9. Hainsworth JD, Greco FA. Managing carcinomas of unknown primary site. Oncology (Huntingt) 1988 ; 2 : 43-4.
10. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986 ; 57 : 120-4.
11. Daugaard G. Unknown primary tumours. Cancer Treat Rev 1994 ; 20 : 119-47.
12. Greco FA, Hainsworth JD. Cancer of unknown primary site. In : De Vita VT, hellman, S, Rosenberg, SA, eds. Principles and practice of oncology. Philadelphia : Lippincott, Raven, 1997.
13. Jordan WE, III, Shildt RA. Adenocarcinoma of unknown primary site. The Brooke Army Medical Center experience. Cancer 1985 ; 55 : 857-60.
14. Levine MN, Drummond MF, Labelle RJ. Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin. CMAJ 1985 ; 133 : 977-87.
15. Muit C. Cancer of unknown primary site. Cancer 1995 ; 75 (1 Suppl) : 353-6.
16. Krementz ET, Cerise EJ, Foster DS, Morgan LR, Metastases of undetermined source. Curr Probl Cancer 1979 ; 4 : 4-37.
17. Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 1995 ; 155 : 2050-4.
18. Federation nationale des centres de lutte contte le cancer. Enquête permanente cancer 1975-1989. Survie à long terme des malades traités pour cancer. Paris : Doin, 1991.
19. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma : natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994 ; 12 : 1272-80.
20. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995 ; 13 : 2094-103.
21. Lortholary A, Abadie-Lacourtoisie S, Guerin O, Mege M, Rauglaudre GD, Gamelin E. Cancers d'origine indéterminée : à propos de 311 cas. Bull Cancer 2001 ; 88 : 619-27.
22. Hillen HF. Unknown primary tumours. Postgrad Med J 2000 ; 76 : 690-3.
23. Leonard RJ, Nystrom JS. Diagnostic evaluation of patients with carcinoma of unknown primary tumor site. Semin Oncol 1993 ; 20 : 244-50.
24. Mayordomo JI, Guerta JM, Guijarro C, Garcia-Prats MD, Gomez A, Lopez-Brea M, et al. Neoplasms of unknown primary site : a clinicopathological study of autopsied patients. Tumori 1993 ; 79 : 321-4.
25. NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network. Oncology (Huntingt) 1998 ; 12 (11A) : 226-309.
26. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993 ; 329 : 257-63.
27. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999 ; 5 : 3403-10.
28. Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol 1986 ; 4 : 1652-7.
29. nd ed. London : Churchill Livingstone, 2000 ; 1-5.
30. Saint-Andre JP, Donzel JP, Anger E, Chatelet F, Cochand-Priollet B, de Graeve P, et al. Practice guidelines in pathologic anatomy and cytology. Document prepared by the French Association of Quality Assurance in Pathologic Anatomy and Cytology (AFAQAP). Commission No. 4 : organization and functioning of Pathologic Anatomy and Cytology. Ann Pathol 1998 ; 18 : 227-36.
31. Plenat F, Antunes L, Haller T, Piet-Ounnoughene M, Klein-Monhoven N, Champigneulle J, et al. Formaldehyde fixation in the third millennium. Ann Pathol 2001 ; 21 : 29-47.
32. Denoux Y, Blanc-Vincent MP, Simony-Lafontaine J, Verriele-Beurrier V, Briffod M, Voigt JJ. Standards, Options et Recommandations : Bonne pratique de l'acheminement et de la prise en charge initiale d'un prélèvement en anatomie et cytologie pathologiques en cancérologie. Bull Cancer 2002 ; 89 : 401-9.
33. Reyes CV, Thompson KS, Jensen JD, Choudhury AM. Metastasis of unknown origin : the role of fine-needle aspiration cytology. Diagn Cytopathol 1998 ; 18 : 319-22.
34. Turbat-Herrera EA, Knowles K, Cytology : screening or diagnostic tool ? Hum Pathol 1998 ; 29 : 1356-66.
35. Motzer RJ, Rodriguez E, Reurer VE, Bosl GJ, Mazumdar M, Chaganti RS. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995 ; 13 : 274-82.
36. Oliveira AM, Erickson LA, Burgatt LJ, Lloyd RV. Differentiation of primary and metastatic clear cell tumors in the liver by in situ hybridization for albumin messenget RNA. Am J Surg Pathol 2000 ; 24 : 177-82.
37. Ilson DH, Motzet RJ, Rodriguez E, Chaganti RS, Bosl GJ. Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. Semin Oncol 1993 ; 20 : 229-37.
38. Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 1998 ; 29 : 1393-402.
39. Ordonez NG, Mackay B. Electron microscopy in tumor diagnosis : indications for its use in the immunohistochemical era. Hum Pathol 1998 ; 29 : 1403-11.
40. Chan JK. Advances in immunohistochemistry : impact on surgical pathology practice. Semin Diagn Pathol 2000 ; 17 : 170-7.
41. Gamble AR, Bell JA, Ronan JE, Pearson D, Ellis IO. Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. Br Med J 1993 ; 306 : 295-8.
42. Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA. Poorly differentiated carcinoma of unknown primary site : clinical usefulness of immunoperoxidase staining. J Clin Oncol 1991 ; 9 : 1931-8.
43. Mackay B, Ordonez NG. Pathological evaluation of neoplasms with unknown primary tumor site. Semin Oncol 1993 ; 20 : 206-28.
44. Voigt JJ, Delsol G. Paraffin section immunohistochemistry. Contributions and limitations. Ann Pathol 1992 ; 12 : 58-60.
45. Barr NJ, Taylor RC. Approach to the "unknown primary" anaplastic tumors. In : Taylor RC, Cote RJ, eds. Immunomicroscopy : a diagnostic tool for the surgical pathologist. 2nd ed. Philadelphia : W.B. Saunders Company, 1994.
46. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin : an algorithmic approach. Semin Diagn Pathol 2000 ; 17 : 184-93.
47. Gown AM. Cost effective immunohistochemistry. 85th annual meeting. United States and Canadian Academy of Pathology ; Washington 1996.
48. Gown AM, Bacchi CE. Diagnostic immunohistochemistry of solid tumors : strategies and solutions. 91st annual meeting. United States and Canadian Academy of Pathology ; Chicago 2002.
49. De Gramont A, Louvet C, Krulik M. Cancers de foyets primitifs inconnus. Rev Prat 1995 ; 9 : 30-3.
50. Greco FA, Hainsworth JD. Tumors of unknown origin. CA Cancer J Clin 1992 ; 42 : 96-115.
51. Hainsworth JD, Greco FA. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site. Semin Oncol 1993 ; 20 : 279-86.
52. Bacchi CE, Bonetti F, Pea M, Martignoni G, Gown AM. HMB-45. A review. Appl Immunohistochem 1996 ; 4 : 73-85.
53. Battifora H, Mc Caughey WTE. Tumors of the serosal membranes. In : Atlas of tumor pathology. 3rd ed. Washington : AFIP, 1995.
54. Millward C, Weidner N. CD30 (Bet-H2) expression in nonhematopoietic tumors. Appl Immunohistochem 1998 ; 6 : 164-8.
55. Kaufman O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markets of the differential diagnosis of poorly diffetentiated and undifferentiated carcinomas. Am J Clin Pathol 2001 ; 116 : 823-30.
56. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordonez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin : favorable subsets of patients with unknown-primary carcinoma ? J Clin Oncol 1997 ; 15 : 2056-66.
57. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol 1998 ; 16 : 2105-12.
58. Leroy X, Copin MC, Boman F, Gosselin B. Cytokeratins 7 and 20 : aid in tumor typing. Ann Pathol 1998 ; 18 : 103-9.
59. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms : a survey of 435 cases. Mod Pathol 2000 ; 13 : 962-72.
60. Wang PN, Zee S, Zarbo RJ, Bacchi CE, Gown AM. Coordinate expression of cytokeratins 7 and 20. Defines unique subsets of carcinomas. Appl Immunohistochem 1995 ; 3 : 99-107.
61. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJ. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry : differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998 ; 29 : 491-7.
62. Sheahan K, O'Keane JC, Abramowitz A, Carlson JA, Burke B, Gottlieb LS, et al. Metastatic adenocarcinoma of an unknown primary site. A comparison of the relative contributions of morphology, minimal essential clinical data and CEA immunostaining status. Am J Clin Pathol 1993 ; 99 : 729-35.
63. Leong AS, Sormunen RT, Tsui WM, Liew CT. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology 1998 ; 33 : 318-24.
64. Levesque M, Yu H, D'Costa M, Tadross L, Diamandis EP. Immunoreactive prostate-specific antigen in lung tumors. J Clin Lab Anal 1995 ; 9 : 375-9.
65. Yu H, Diamandis EP, Levesque M, Asa SL, Monne M, Croce CM. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 1995 ; 55 : 1603-6.
66. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000 ; 36 : 8-16.
67. Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol 2000 ; 7 : 123-7.
68. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 1999 ; 52 : 283-90.
69. Bacchi CE, Garcia RL, Gown AM. Immunolocalization of estrogen and progesterone receptors in neuroendocrine tumors of lung, skin, gastrointestinal and female genital tracts. Appl Immunohistochem 1997 ; 5 : 17-22.
70. Canver CC, Memoli VA, Vanderveer PL, Dingivan CA, Mentzer RM, Jr. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg 1994 ; 108 : 153-7.
71. Merson M, Andreola S, Galimberti V, Bufalino R, Marchini S, Veronesi U. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 1992 ; 70 : 504-8.
72. Wallace ML, Longacre TA, Smoller BR. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Mod Pathol 1995 ; 8 : 897-901.
73. Wick MR, Ockner DM, Mills SE, Rirrer JH, Swanson PE. Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol 1998 ; 109 : 75-84.
74. Garalica Z, Miettinen M. Distribution of carcinoma antigens Ca 19-9 and Ca 15-3. An immunohistochemical study of 400 tumors. Appl Immunohistochem 1994 ; 2 : 205-11.
75. Quenneville L, Yazizi H, Gown AM. WT1 is a sensitive and specific marker of serous, but not mucinous, ovarian carcinomas. Mod Pathol 2001 ; 14 : 145A.
76. Harach HR, Franssila KO. Thyroglobulin immunostaining in follicular thyroid carcinoma : relationship to the degree of differentiation and cell type. Histopathology 1988 ; 13 : 43-54.
77. Shimonishi T, Miyazaki K, Nakanuma Y. Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver. Histopathology 2000 ; 37 : 55-63.
78. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol 2000 ; 113 : 683-7.
79. Jones AS, Phillips DE, Helliwell TR, Roland NJ. Occult node metastases in head and neck squamous carcinoma. Eur Arch Otorhinolaryngol 1993 ; 250 : 446-9.
80. Gerald WL, Miller HK, Battifora H, Miettinen M, Silva EG, Rosai J. Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol 1991 ; 15 : 499-513.
81. Leuschner I, Radig K, Harms D. Desmoplastic small round cell tumor. Semin Diagn Pathol 1996 ; 13 : 204-12.
82. Mousseau M, Schaerer R, Lutz JM, Menegoz F, Faure H, Swiercz P. Hepatic metastasis of unknown primary site. Bull Cancer 1991 ; 78 : 725-36.
83. Gaffey MJ, Mills SE, Frierson HF, Askin FB, Maygarden SJ. Pulmonary clear cell carcinoid tumor : another entity in the differential diagnosis of pulmonary clear cell neoplasia. Am J Surg Pathol 1998 ; 22 : 1020-5.
84. Nappi O, Mills SE, Swanson PE, Wick MR. Clear cell tumors of unknown nature and origin : a systematic approach to diagnosis. Semin Diagn Pathol 1997 ; 14 : 164-74.
85. Savera AT, Torres FX, Linden MD, Bacchi CE, Gown AM, Zarbo RJ. Primary versus metastatic pulmonary adenocarcinoma. A immunohistochemical study using villin and cytokeratins 7 and 20. Appl Immunohistochem 1996 ; 4 : 86-94.
86. Perry A, Parisi JE, Kurtin PJ. Metastatic adenocarcinoma to the brain : an immunohistochemical approach. Hum Pathol 1997 ; 28 : 938-43.
87. Arber JM, Arber DA, Jenkins KA, Battifora H. Effect of decalcification and fixation in paraffin-section immunohistochemistry. Appl Immunohistochem 1996 ; 4 : 241-8.
88. Speights VO, Cohen MK, Coffield KS, Keegan GT, Mc Clintock J, Arber DA. Neuroendocrine staining in malignant, hyperplastic, and atrophic prostate tissue. Appl Immunohistochem 1994 ; 2 : 212-7.
89. Byrd-Gloster AL, Khoor A, Glass LF, Messina JL, Whitsett JA, Livingston SK, et al. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol 2000 ; 31 : 58-62.
90. Voigt JJ, Alsaati T, Gorguet B, Caveriviere P, Scarna H, Bugat R, et al. Merkel cell carcinoma of the skin. Anatomoclinical, ultrastructural and immunohistochemical study of 14 cases. Ann Pathol 1985 ; 5 : 195-203.
91. Culine S, Gazagne L, Ychou M, Romieu G, Fabbro M, Cupissol D, et al. Carcinoma of unknown primary site. Apropos of 100 patients treated at the Montpellier regional center of cancer prevention. Rev Med Interne 1998 ; 19 : 713-9.
92. Fizazi K, Culine S. Metastatic carcinoma of unknown origin. Bull Cancer 1998 ; 85 : 609-17.
93. Stewart JF, Tartersall MH, Woods RL, Fox RM. Unknown primary adenocarcinoma : incidence of overinvestigation and natural history. Br Med J 1979 ; 1 : 1530-3.
94. Steckel RJ, Kagan AR. Metastatic tumors of unknown origin. Cancer 1991 ; 67 (4 Suppl) : 1242-4.
95. Abbruzzese JL, Abbruzzese MC, Lenzi R, Raber MN, Hess KR. Are time or intensity factors important to the definition of metastases of unknown origin ? J Natl Cancer Inst 1996 ; 88 : 462-3.
96. Hamilton CS, Langlands AO. ACUPS (adenocarcinoma of unknown primary site) : a clinical and cost benefit analysis. Int J Radiat Oncol Biol Phys 1987 ; 13 : 1497-503.
97. Karsell PR, Sheedy PF, O'Connell MJ. Computed tomography in search of cancer of unknown origin. JAMA 1982 ; 248 : 340-3.
98. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, et al. Early metastatic cancer of unknown primary origin at presentation : a clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988 ; 148 : 2035-9.
99. McMillan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site : a retrospective study. Radiology 1982 ; 143 : 143-6.
100. Moerrel CG, Reitemeier RJ, Schurt AJ, Hahn RG. Treatment of the patient with adenocarcinoma of unknown origin. Cancer 1972 ; 30 : 1469-72.
101. Nystrom JS, Weiner JM, Wolf RM, Bareman JR, Viola MV. Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. JAMA 1979 ; 241 : 381-3.
102. Shildt RA, Kennedy PS, Chen TT, Athens JW, O'Bryan RM, Balcerzak SP. Management of patients with metastatic adenocarcinoma of unknown origin : a Southwest Oncology Group study. Cancer Treat Rep 1983 ; 67 : 77-9.
103. Walsh JW, Rosenfield AT, Jaffe CC, Schwarrz PE, Simeone J, Dembner AG, et al. Prospective comparison of ultrasound and computed tomography in the evaluation of gynecologic pelvic masses. Am J Roentgenol 1978 ; 131 : 955-60.
104. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2001 ; 12 : 1057-8.
105. Beretta GD, Pessi MA, Poletri P, Mosconi S, Labianca R. New drugs and combinations in the palliative treatment of colon and rectal cancer. Eur J Surg Oncol 2001 ; 27 : 595-600.
106. Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 1990 ; 66 : 1461-7.
107. Patel J, Nemoto T, Rosner D, Dao TL, Pickren JW. Axillary lymph node metastasis from an occult breast cancer. Cancer 1981 ; 47 : 2923-7.
108. De Wit R, Hoek FJ, Bakker PJ, Veenhof CH. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites. J Intern Med 1991 ; 229 : 463-6.
109. Ruddon RW, Norton SE. Use of biological markers in the diagnosis of cancers of unknown primary tumor. Semin Oncol 1993 ; 20 : 251-60.
110. Pavlidis N, Kalef-Ezra J, Briassoulis E, Skarlos D, Kosmidis P, Saferiadis K, et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 1994 ; 22 : 162-7.
111. Boutguet P, Blanc-Vincent MP, Boneu A, Chauffert B, Corone C, Coutbon F, et al. Standards, Options et Recommandations pour l'utilisation de la tomographie par émission de positons au [18F]-FDG (TEP-FDG) en cancérologie [online]. Fédération nationale des centres de lutte contre le cancer, ed. 2002. Available : URL : http ://www.fnclcc.fr/-sci/ sot/pdf/ tep-fdg-integrale-0202.pdf
112. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer : an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999 ; 17 : 3201-6.
113. Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998 ; 82 ; 1160-6.
114. Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999 ; 35 : 1076-82.
115. AAssar OS, Fischbein NJ, Caputo GR, Kaplan MJ, Price DC, Singer MI, et al. Metastatic head and neck cancer : role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999 ; 210 : 177-81.
116. Jungehulsing M, Scheidhauer K, Damm M, Pietrzyk U, Eckel H, Schicha H, et al. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000 ; 123 : 294-301.
117. Greven KM, Keyes JW, Jr., Williams DW, III, McGuirt WF, Joyce WT, III. Occult primary tumors of the head and neck : lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer 1999 ; 86 : 114-8.
118. Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000 ; 41 : 816-22.
119. Bohuslavizki KH, Klutmann S, Sonnemann U, Thorns J, Kroger S, Wetner JA, et al. F-18-FDG-PET zur Detekrion des okkulten Primartumors bei Parienren mir Lymphknorenmetasrasen der Halsregion. Laryngorhinootologie 1999 ; 78 : 445-9.
120. Braams JW, Pruim J, Kole AC, Nikkels PG, Vaalburg W, Vermey A, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997 ; 26 : 112-5.
121. Haenggeli CA, Dulguerov P, Slosman D, Becker M, Bang P, Allal A, et al. Rôle de la tomographie par émission de positrons avec le 18-fluoro-deoxyglucose (PET-FDG) dans la dérecrion précoce d'une non-stérilisation rumorale des carcinomes bucco-pharyngo-laryngés. Schweiz Med Wochenschr 2000 ; 116 (suppl) : 8S-11S.
122. Safa AA, Tran LM, Rege S, Brown CV, Mandelkern MA, Wang MB, et al. The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am 1999 ; 5 : 214-8.
123. Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography. Oral Oncol 1999 ; 35 : 390-4.
124. Rades D, Kuhnel G, Wildfang I, Borner AR, Schmoll HJ, Knapp W. Localised disease in cancer of unknown primary (CUP) : the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001 ; 12 : 1605-9.
125. Kagan AR, Steckel RJ. The limited role of radiologic imaging in patients with unknown tumor primary. Semin Oncol 1991 ; 18 : 170-3.
126. Maiche AG. Cancer of unknown primary. a retrospective study based on 109 patients. Am J Clin Oncol 1993 ; 16 : 26-9.
127. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site : recognition of a treatable syndrome. Ann Intern Med 1986 ; 104 : 547-53.
128. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site : results of a 12-year experience. J Clin Oncol 1992 ; 10 : 912-22.
129. Richardson RL. Germ cell cancers. Ann Intern Med 1981 ; 95 : 521.
130. Bhatia SK, Saclarides TJ, Witt TR, Bonomi PD, Anderson KM, Economou SG. Hormone receptor studies in axillary metastases from occult breast cancers. Cancer 1987 ; 59 : 1170-2.
131. Fizazi K, Culine S, Droz JP, Kramar A, Theodore C, Ruffle P, et al. Primary mediastinal nonseminomatous germ cell tumors : results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol 1998 ; 16 : 725-32.
132. Lemarie E, Assouline PS, Diot P, Regnard JF, Levasseur P, Droz JP, et al. Primary mediastinal germ cell tumors. Results of a French retrospective study. Chest 1992 ; 102 : 1477-83.
133. Greco FA, Hainsworth JD. Carcinoma of unknown primary site. Ann Oncol 1990 ; 1 : 98-9.
134. van der Gaast A, Verweij J, Henzen-Logmans SC, Rodenburg CJ, Stoter G. Carcinoma of unknown primary : identification of a treatable subset ? Ann Oncol 1990 ; 1 : 119-22.
135. Garrow GC, Greco FA, Hainsworth JD. Poorly differentiated neuroendocrine carcinoma of unknown primary tumor site. Semin Oncol 1993 ; 20 : 287-91.
136. Motzer RJ, Rodriguez E, Reuter VE, Samaniego F, Dmitrovsky E, Bajorin DF, et al. Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. J Natl Cancer Inst 1991 ; 83 : 341-6.
137. Weber A, Schmoz S, Bootz F. CUP (carcinoma of unknown primary) syndrome in head and neck : clinic, diagnostic, and therapy. Onkologie 2001 ; 24 : 38-43.
138. Igenberg QS, Yarbro JW. Presentation and clinical syndromes of tumors of unknown origin. In : Fer MF, Greco, FA, Oldham, RK, eds. Poorly differentiated neoplasms and tumors of unkown origin. New York : Grüne, Statton, 1986.
139. Feinmesser R, Miyazaki I, Cheung R, Freeman JL, Noyek AM, Dosch HM. Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. N Engl J Med 1992 ; 326 : 17-21.
140. Ashikari R, Rosen PP, Urban JA, Senoo T. Breast cancer presenting as an axillary mass. Ann Surg 1976 ; 183 : 415-7.
141. Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Perrek JA. Occult breast cancer presenting with axillary metastases : updated management. Arch Surg 1990 ; 125 : 210-4.
142. Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg 1986 ; 152 : 43-7.
143. Orel SG, Weinstein SP, Schnall MD, Reynolds CA, Schuchter LM, Fraker DL, et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999 ; 212 : 543-9.
144. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys 2000 ; 47 : 143-7.
145. Olson JA, Jr., Morris EA, Van Zee KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000 ; 7 : 411-5.
146. Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M. MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat 1997 ; 44 : 179-82.
147. Lenzi R, Kim EE, Raber MN, Abbruzzese JL. Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111 In-pentetreotide scan. Ann Oncol 1998 ; 9 : 213-6.
148. Chiti A, Di Nicola M, Spinelli A, Siena S, Btegni M, Savelli G, et al. A case of metastatic axillary lymph nodes involvement from unknown primary cancer : clinical usefulness of [99mTc]-sestamibi. Tumori 1998 ; 84 : 612-3.
149. Block EF, Meyet MA. Positron emission tomography in diagnosis of occult adenocarcinoma of the breast. Am Surg 1998 ; 64 : 906-8.
150. Faure E, Riquet M, Lombe-Weta PM, Hubsch JP, Carnot F. Malignant mediastinal lymph node tumors with unknown primary cancers. Rev Mal Respir 2000 ; 17 : 1095-9.
151. Turrisi AT, III, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999 ; 340 : 265-71.
152. Zaren HA, Copeland EM, III. Inguinal node metastases. Cancer 1978 ; 41 : 919-23.
153. Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger H, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma : recommendations for initial staging examinations. Cancer 1997 ; 80 : 60-5.
154. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998 ; 16 : 1075-84.
155. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998 ; 16 : 2113-25.
156. Sherwin RP. The differentiation of primary lung cancer from metastases. In : Weiss L, Gilbert, HA, eds. Pulmonary metastases. Boston : Hall GK, 1978.
157. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusions. Eur Respir J 2001 ; 18 : 402-19.
158. Kayser K, Bohm G, Blum S, Beyer M, Zink S, Andre S, et al. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. J Pathol 2001 ; 193 : 175-80.
159. Bonnefoi H, Smith IE. How should cancer presenting as a malignant pleural effusion be managed ? Br J Cancer 1996 ; 74 : 832-5.
160. Dalrymple JC, Bannatyne P, Russell P, Solomon HJ, Tattersall MH, Atkinson K, et al. Extraovarian peritoneal setous papillary carcinoma : a clinicopathologic study of 31 cases. Cancer 1989 ; 64 : 110-5.
161. Fowler JM, Nieberg RK, Schooler TA, Berek JS. Peritoneal adenocarcinoma (serous) of mulletian type : a subgroup of women presenting with peritoneal carcinomatosis. Int J Gynecol Cancer 1994 ; 4 : 43-51.
162. Muggia FM, Batanda J. Management of peritoneal carcinomatosis of unknown primary tumor site. Semin Oncol 1993 ; 20 : 268-72.
163. Zhou J, Iwasa Y, Konishi I, Kan N, Kannagi R, Kobashi Y, et al. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Cancer 1995 ; 76 : 429-36.
164. Shah IA, Jayram L, Gani OS, Fox IS, Stanley TM. Papillary serous carcinoma of the peritoneum in a man : a case report. Cancer 1998 ; 82 : 860-6.
165. Wedin R, Bauer HC, Skoog L, Soderlund V, Tani E. Cytological diagnosis of skeletal lesions. Fine-needle aspiration biopsy in 110 tumours. J Bone Joint Surg Br 2000 ; 82 : 673-8.
166. Tell DT, Khoury JM, Taylor HG, Veasey SP. Atypical metastasis from prostate cancer. Clinical utility of the immunoperoxidase technique for prostate-specific antigen. JAMA 1985 ; 253 : 3574-5.
167. Villers A, Pommier P, Bataillard A, Pervers B, Bachaud JM, Berger N, et al. Fédération nationale des centres de lutte contre le cancer, ed. Standards, Options et Recommandations : cancer de la prostate non métastatique. Paris : FNCLCC, John Libbey Eurotext, 2002. Standards, Options, Recommandations, vol. 14.
168. Alcalay M, Azais I, Brigeon B, Babin P, Vandermarcq P, Debiais F, etal. Strategy for identifying primary malignancies with inaugural bone metastases. Rev Rhum Engl Ed 1995 ; 62 : 632-42.
169. Rougraff BT, Kneisl JS, Simon MA. Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am 1993 ; 75 : 1276-81.
170. Katagiri H, Takahashi M, Inagaki J, Sugiuta H, Ito S, Iwata H. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin : a retrospective study [Comment in : Cancer 2000 ; 88 : 1759-61]. Cancer 1999 ; 86 : 533-7.
171. Brage ME, Simon MA. Evaluation, prognosis, and medical treatment considerations of metastatic bone tumors. Orthopedics 1992 ; 15 : 589-96.
172. Shih LY, Chen TH, Lo WH. Skeletal metastasis from occult carcinoma. J Surg Oncol 1992 ; 51 : 109-13.
173. Mysorekar W, Dandekar CP, Rao SG. Metascatic bone tumours. J Indian Med Assoc 1998 ; 96 : 74-6.
174. van de Pol M, van Aalst VC, Wilmink JT, Twijnstta A. Brain metastases from an unknown primary tumour : which diagnostic procedures are indicated ? J Neurol Neurosurg Psychiatry 1996 ; 61 : 321-3.
175. Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer : Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001 ; 12 : 59-67.
176. Gabalski EC, Belles W. Management of the unknown primary in patients with metastatic cancer of the head and neck. Ear Nose Throat J 2000 ; 79 : 306-3.
177. Fernandez JA, Suarez C, Martinez JA, Llorente JL, Rodrigo JP, Alvarez JC. Metastatic squamous cell carcinoma in cervical lymph nodes from an unknown primary tumour : prognostic factors. Clin Otolaryngol 1998 ; 23 : 158-63.
178. McCunniff AJ, Raben M. Metastatic carcinoma of the neck from an unknown primary. Int J Radiat Oncol Biol Phys 1986 ; 12 : 1849-52.
179. Carlson LS, Fletcher GH, Oswald MJ. Guidelines for radiotherapeutic techniques for cervical metastases from an unknown primary. Int J Radiat Oncol Biol Phys 1986 ; 12 : 2101-10.
180. Davidson BJ, Spiro RH, Patel S, Patel K, Shah JP. Cervical metastases of occult origin : the impact of combined modality therapy. Am J Surg 1994 ; 168 : 395-9.
181. De Braud F, Al Sarraf M. Diagnosis and management of squamous cell carcinoma of unknown primary tumor site of the neck. Semin Oncol 1993 ; 20 : 273-8.
182. Fletcher GH. Controversial issues in the management of cervical metastases [Comment on : Int J Radiat Oncol Biol Phys 1990 ; 19 : 919-28]. Int J Radiat Oncol Biol Phys 1990 ; 19 : 1101-2.
183. Gluckman JL, Robbins KT, Fried MP. Cervical metastatic squamous carcinoma of unknown or occult primary source [Comment in : Head Neck 1991 ; 13 : 553]. Head Neck 1990 ; 12 : 440-3.
184. Jesse RH, Perez CA, Fletcher GH. Cervical lymph node metastasis : unknown primary cancer. Cancer 1973 ; 31 : 854-9.
185. Leipzig B, Winter ML, Hokanson JA. Cervical nodal metastases of unknown origin. Laryngoscope 1981 ; 91 : 593-8.
186. Marcial-Vega VA, Cardenes H, Perez CA, Devineni VR, Simpson JR, Fredrickson JM, et al. Cervical metastases from unknown primaries : radiotherapeutic management and appearance of subsequent primaries [Comment in : Int J Radiat Oncol Biol Phys 1990 ; 19 : 1101-2]. Int J Radiat Oncol Biol Phys 1990 ; 19 : 919-28.
187. Jones AS, Cook JA, Phillips DE, Roland NR. Squamous carcinoma presenting as an enlarged cervical lymph node [Comment in : Cancer 1994 ; 73 : 2008-10]. Cancer 1993 ; 72 : 1756-61.
188. Lapeyre M, Malissard L, Peiffert D, Hoffstetter S, Toussaint B, Renier S, et al. Cervical lymph node metastasis from an unknown primary : is a tonsillectomy necessary ? Int J Radiat Oncol Biol Phys 1997 ; 39 : 291-6.
189. Renaud-Salis JL, Blanc-Vincent MP, Brugère J, Demard F, Faucher A, Gory-Delabaere G, et al. Standards, Options et Recommandations pour le diagnostic, le traitement et la surveillance des cancers épidermoï des de l'oropharynx. Bull Cancer 1999 ; 86 : 550-72.
190. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. WHO International Histological Typing of tumours. Berlin : Springer, 2000.
191. Cadiot G, Lebtahi R, Sarda L, Bonnaud G, Marmuse JP, Vissuzaine C, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe d'étude du syndrome de Zollinger-Ellison. Gastroenterology 1996 ; 111 : 845-54.